Repligen (NASDAQ:RGEN) Earns Overweight Rating from Analysts at Barclays

Barclays started coverage on shares of Repligen (NASDAQ:RGEN - Get Free Report) in a research report issued to clients and investors on Tuesday,Briefing.com Automated Import reports. The brokerage set an "overweight" rating and a $150.00 price target on the biotechnology company's stock. Barclays's price target would suggest a potential upside of 24.89% from the stock's previous close.

RGEN has been the subject of a number of other reports. Royal Bank Of Canada lowered their price target on Repligen from $202.00 to $189.00 and set an "outperform" rating for the company in a research report on Wednesday, April 30th. Wolfe Research upgraded Repligen from a "peer perform" rating to an "outperform" rating and set a $160.00 price objective on the stock in a research note on Tuesday, April 29th. JPMorgan Chase & Co. reduced their target price on Repligen from $200.00 to $190.00 and set an "overweight" rating for the company in a report on Tuesday, April 29th. Wall Street Zen raised shares of Repligen from a "hold" rating to a "buy" rating in a report on Saturday. Finally, Evercore ISI began coverage on shares of Repligen in a report on Tuesday, March 18th. They set an "in-line" rating and a $155.00 target price on the stock. Four equities research analysts have rated the stock with a hold rating and eleven have issued a buy rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and an average price target of $171.46.

Repligen Stock Up 1.1%

Shares of RGEN opened at $120.11 on Tuesday. The company has a debt-to-equity ratio of 0.27, a quick ratio of 5.79 and a current ratio of 6.79. Repligen has a 52 week low of $102.97 and a 52 week high of $182.52. The stock has a market capitalization of $6.75 billion, a price-to-earnings ratio of -266.91, a PEG ratio of 3.40 and a beta of 1.11. The stock has a fifty day moving average of $128.57 and a 200-day moving average of $141.68.

Repligen (NASDAQ:RGEN - Get Free Report) last released its quarterly earnings results on Tuesday, April 29th. The biotechnology company reported $0.39 earnings per share for the quarter, topping the consensus estimate of $0.35 by $0.04. Repligen had a positive return on equity of 4.53% and a negative net margin of 3.93%. The company had revenue of $169.17 million for the quarter, compared to analysts' expectations of $163.65 million. During the same period in the previous year, the business posted $0.28 earnings per share. The business's quarterly revenue was up 10.4% compared to the same quarter last year. As a group, sell-side analysts anticipate that Repligen will post 1.72 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the business. CIBC Asset Management Inc boosted its stake in shares of Repligen by 5.0% in the 4th quarter. CIBC Asset Management Inc now owns 1,706 shares of the biotechnology company's stock valued at $246,000 after purchasing an additional 81 shares in the last quarter. Alliance Wealth Advisors LLC UT boosted its position in Repligen by 2.5% during the first quarter. Alliance Wealth Advisors LLC UT now owns 3,675 shares of the biotechnology company's stock valued at $468,000 after buying an additional 89 shares during the period. Utah Retirement Systems grew its stake in shares of Repligen by 1.1% during the fourth quarter. Utah Retirement Systems now owns 9,294 shares of the biotechnology company's stock valued at $1,338,000 after buying an additional 100 shares during the last quarter. State of Michigan Retirement System increased its holdings in shares of Repligen by 0.8% in the first quarter. State of Michigan Retirement System now owns 12,453 shares of the biotechnology company's stock worth $1,585,000 after buying an additional 100 shares during the period. Finally, Louisiana State Employees Retirement System lifted its stake in shares of Repligen by 0.7% in the 1st quarter. Louisiana State Employees Retirement System now owns 14,600 shares of the biotechnology company's stock valued at $1,858,000 after acquiring an additional 100 shares during the last quarter. 97.64% of the stock is currently owned by institutional investors.

About Repligen

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.